Skip to Main Content

Paper Details

Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.
Diabetes Obes Metab
0
2024
Author NameAffiliation
Kenneth W MahaffeyStanford Center for Clinical Research, Stanford University School of Medicine
  • 1 - 1

Datasets

Release 1.2